AI-Managed Organ Culture Bioreactor OrganFarm Prototype Released: Ex Vivo Organ Survival Extended from 7 Days to 90 Days

AI-Managed Organ Culture Bioreactor OrganFarm Prototype Released

On September 16, 2030, Japan's National Institute for Quantum Science and Technology (QST) released the prototype of the OrganFarm organ culture bioreactor. The system uses AI to real-time regulate culture fluid composition, temperature, pressure, and mechanical stimulation parameters, extending ex vivo organ survival from approximately 12 hours with traditional cold storage to 90 days.

One of the biggest bottlenecks in organ transplantation is the extremely short ex vivo preservation time for donor organs. Traditional cold storage methods (immersing organs in ice-cold preservation solution) preserve hearts for approximately 4 to 6 hours, livers for approximately 12 hours, and kidneys for approximately 24 hours. This means organs must complete transport and transplant surgery from donor to recipient within an extremely short window.

OrganFarm's core concept is to simulate the physiological environment inside the human body. Each organ is placed in a sealed bioreactor, and the AI system adjusts culture parameters in real time based on organ type and current state. For example, for hearts, the system simulates normal blood pressure fluctuations and heartbeat rhythms to apply mechanical stimulation; for lungs, it simulates breathing movements with periodic stretching.

QST project lead Professor Hiroaki Tanaka said: "The key breakthrough is our AI state assessment algorithm. By continuously analyzing biomarkers released by the organ into the culture fluid (such as lactate, creatinine, and inflammatory factors), it adjusts culture parameters before organ function begins to decline."

In animal experiments, OrganFarm successfully maintained pig hearts ex vivo for 87 days (with normal electrical activity and contractile function), pig livers for 72 days (capable of normal drug metabolism), and pig kidneys for over 90 days (capable of producing urine).

OrganFarm is still in prototype stage and requires extensive safety validation before human organ application. QST plans to initiate the first human organ (kidney) OrganFarm culture trial in 2031.

The project received funding from the Japan Science and Technology Agency (JST), with a total budget of approximately 3 billion yen (approximately $20 million).